SCHEDULE: Avoro Capital Advisors Discloses 9.87% Stake in uniQure

Avoro Capital Advisors and Behzad Aghazadeh have reported a 9.87% beneficial ownership stake in uniQure N.V., holding 6,150,000 ordinary shares.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in uniQure N.V.
• The Reporting Persons collectively beneficially own 6,150,000 ordinary shares of uniQure N.V.
• This ownership represents 9.87% of uniQure N.V.'s outstanding ordinary shares.
• The percentage is calculated based on 62,291,663 shares outstanding as of November 6, 2025, as reported in uniQure's Form 10-Q for the quarter ended September 30, 2025.
• Avoro Capital Advisors LLC, a Delaware limited liability company, provides investment advisory and management services, acquiring shares for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• Dr. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of uniQure N.V.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial 9.87% stake by Avoro Capital Advisors, a specialized life sciences investor, suggests confidence in uniQure N.V.'s value proposition and future prospects.

Positives

• A significant beneficial ownership stake (9.87%) by an investment firm specializing in life sciences (Avoro Life Sciences Fund LLC) may signal confidence in uniQure N.V.'s long-term prospects.
• The investment is stated to be for investment purposes in the ordinary course of business, not for control, suggesting a passive but substantial vote of confidence.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding uniQure N.V.'s future performance or strategic direction.

Management Comments

• Avoro Capital Advisors LLC acquired the ordinary shares of uniQure N.V. solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that significant institutional ownership, particularly from specialized life sciences funds like Avoro Life Sciences Fund LLC, can be a positive indicator in the biotechnology sector, often reflecting a belief in the long-term potential of a company's pipeline or technology. This filing indicates continued interest and a substantial stake in uniQure N.V. by a prominent investor in the space.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lend credibility and stability to the stock, potentially attracting further investor interest.

Key Dates

Recommendation

The disclosure of a nearly 10% stake by a specialized life sciences investment firm, Avoro Capital Advisors, indicates a strong vote of confidence in uniQure N.V. from a sophisticated investor. This suggests that the stock is considered a valuable long-term holding. However, without additional operational or financial updates from uniQure N.V. itself, a 'hold' recommendation is appropriate, acknowledging the positive signal of institutional backing while awaiting further company-specific performance data.

Keywords

uniQure N.V., Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, Schedule 13G, Ordinary Shares, Biotechnology Investment, Institutional Ownership, N90064101